Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5;15(1):288.
doi: 10.1186/s13104-022-06183-0.

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Daisuke Gotoh  1   2 , Kazumasa Torimoto  3 , Yosuke Morizawa  1 , Shunta Hori  1 , Yasushi Nakai  1 , Makito Miyake  1 , Kiyohide Fujimoto  1
Affiliations

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Daisuke Gotoh et al. BMC Res Notes. .

Abstract

Objective: To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride.

Results: Twenty-four patients were enrolled. The participants had a median age of 71.0 (64.8-73.0) years and a median prostate volume of 37.3 (29.7-41.8) mL as measured using transabdominal sonography. The efficacy indicators, such as International Prostate Symptom Score (IPSS), quality of life (QOL) score, night-time urinary frequency, and night-time maximum voided volume, improved significantly at 4 weeks, and the effects lasted until 24 weeks (IPSS: 9.5 vs. 17.0, QOL: 2.0 vs. 4.0, nocturia: 2.0 vs. 2.0, night-time maximum voided volume: 290.0 vs. 240.0 mL). Overactive bladder symptom score (OABSS) and sexual health inventory for men (SHIM) significantly improved at 12 weeks, and the effects lasted until 24 weeks (OABSS: 3.0 vs. 5.0, SHIM: 11.0 vs. 7.5). However, maximum urine flow and residual urine volume showed no improvement at any point. Adverse events occurred in two cases. Taken together, add-on therapy with tadalafil was effective for patients with LUTS/BPH resistant to dutasteride monotherapy. In addition, this therapy was not associated with severe adverse events.

Keywords: Benign prostatic hyperplasia; Dutasteride; Phosphodiesterase type 5 inhibitor; Tadalafil.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Illustration of the study protocol. The efficacy measures included IPSS, QOL score, OABSS, SHIM, UFM, and FVC at baseline and 4, 12, and 24 weeks after administration of tadalafil. Safety was evaluated based on the patient-reported adverse events during visits. IPSS, International Prostate Symptom Score; QOL, Quality of life; OABSS, overactive bladder symptom score; SHIM, sexual health inventory for men; UFM, uroflowmetry; FVC, frequency volume chart
See this image and copyright information in PMC

Comment in

  • Benign Prostatic Hyperplasia.
    Kaplan SA. Kaplan SA. J Urol. 2023 Apr;209(4):785-787. doi: 10.1097/JU.0000000000003170. Epub 2023 Jan 18. J Urol. 2023. PMID: 36651139 No abstract available.

References

    1. Kupelian V, Wei JT, O’Leary MP, Kusek JW, Litman HJ, Link CL, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381–2387. doi: 10.1001/archinte.166.21.2381. - DOI - PubMed
    1. Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32:230–237. doi: 10.1002/nau.22295. - DOI - PubMed
    1. Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol. 1995;154:391–395. doi: 10.1016/S0022-5347(01)67059-9. - DOI - PubMed
    1. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol. 1996;155:1324–1327. doi: 10.1016/S0022-5347(01)66256-6. - DOI - PubMed
    1. Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn. 2013;32:1123–1127. doi: 10.1002/nau.22349. - DOI - PubMed

MeSH terms